Literature DB >> 19357764

Is it safe to switch from stavudine to zidovudine after developing symptomatic hyperlactatemia?

Barbara Castelnuovo1, Agnes Nanyonjo, Moses Kamya, Ponsiano Ocama.   

Abstract

INTRODUCTION: In resource limited settings patients on antiretroviral treatment who develop stavudine induced hyperlactatemia are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative. CASE REPORT: We describe here a case of a 60 year old female that experienced a relapse of symptomatic hyperlactatemia after being switched from stavudine to zidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda. DISCUSSION: This case shows that switching to zidovudine potentially can lead to a hyperlactatemia relapse. Therefore we recommend close follow up for patients that are switched from stavudine to zidovudine and, in case lactate measurement is not possible, free programs should provide safer drugs such as abacavir and tenofovir for patients that develop hyperlactatemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19357764      PMCID: PMC2584324     

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  8 in total

Review 1.  Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature.

Authors:  K Sundar; M Suarez; P E Banogon; J M Shapiro
Journal:  Crit Care Med       Date:  1997-08       Impact factor: 7.598

2.  Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.

Authors:  K Boubaker; M Flepp; P Sudre; H Furrer; A Haensel; B Hirschel; K Boggian; J P Chave; E Bernasconi; M Egger; M Opravil; M Rickenbach; P Francioli; A Telenti
Journal:  Clin Infect Dis       Date:  2001-10-23       Impact factor: 9.079

3.  A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

Authors:  A Carr; J Miller; M Law; D A Cooper
Journal:  AIDS       Date:  2000-02-18       Impact factor: 4.177

4.  A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa.

Authors:  M G Bolhaar; A S Karstaedt
Journal:  Clin Infect Dis       Date:  2007-06-08       Impact factor: 9.079

5.  Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors.

Authors:  Graeme J Moyle; Debasis Datta; Sundhiya Mandalia; John Morlese; David Asboe; Brian G Gazzard
Journal:  AIDS       Date:  2002-07-05       Impact factor: 4.177

6.  Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine.

Authors:  J Tyler Lonergan; Grace A McComsey; Robin L Fisher; Peter Shalit; Thomas M File; Douglas J Ward; Vanessa C Williams; Siegrid M Hessenthaler; Laura Lindsey; Jaime E Hernandez
Journal:  J Acquir Immune Defic Syndr       Date:  2004-08-01       Impact factor: 3.731

7.  Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis.

Authors:  J Tyler Lonergan; R Edward Barber; W Christopher Mathews
Journal:  AIDS       Date:  2003-11-21       Impact factor: 4.177

8.  Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).

Authors:  Patricia Mwebaze Songa; Barbara Castelnuovo; Estella Birabwa Mugasha; Ponsiano Ocama; Andrew Kambugu
Journal:  Clin Infect Dis       Date:  2007-07-05       Impact factor: 9.079

  8 in total
  3 in total

1.  Welcome to this bumper issue of African Health Sciences.

Authors:  James K Tumwine
Journal:  Afr Health Sci       Date:  2008-06       Impact factor: 0.927

2.  Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.

Authors:  R Kalyesubula; M Kagimu; K C Opio; R Kiguba; C F Semitala; W F Schlech; E T Katabira
Journal:  Afr Health Sci       Date:  2011-03       Impact factor: 0.927

3.  Evaluation of adverse drug reactions in HIV positive patients in a tertiary care hospital.

Authors:  Anshu Kumar Jha; Akash Gadgade; Ashok K Shenoy; Mukta N Chowta; John T Ramapuram
Journal:  Perspect Clin Res       Date:  2015 Jan-Mar
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.